[ad_1]
koto_feja
BioNTech (NASDAQ:BNTX) and Genmab (GMAB) introduced Saturday that their investigational bispecific antibody acasunlimab improved survival charges amongst lung most cancers sufferers together with Merck’s (MRK) immunotherapy Keytruda.
Citing early outcomes from a mid-stage trial for the candidate, the businesses stated acasunlimab with Keytruda, also referred to as pembrolizumab, when administered each six weeks led to 17.5 months of median total survival ((mOS)).
As compared, acasunlimab monotherapy and acasunlimab + pembrolizumab (each three-week dosing schedule) led to mOS charges of 5.5 months and eight.6 months, respectively.
The drug mixture with each six-week dosing schedule was additionally linked to a 12-month total survival fee of 69% amongst sufferers.
The readout was based mostly on an interim evaluation of an ongoing Part 2 trial for 113 sufferers with PD-L(1)-positive metastatic non-small cell lung most cancers.
The tolerability of experimental remedy was consistent with beforehand established security profiles of particular person medicine, and many of the treatment-related adversarial occasions had been Grade 1 and a couple of.
[ad_2]
Source link
